Advanced Accelerator Applications, a subsidiary of global healthcare giant Novartis AG, has announced plans to build a 50,000-square-foot manufacturing plant near Indianapolis International Airport, hiring as many as 50 people to staff the facility.
Financial details were not disclosed.
This will be the company’s second U.S. manufacturing site for currently approved therapy and pipeline drug candidates.
The Radioligand Therapy manufacturing plant will be located within the Purdue Research Park in Indianapolis. The site will produce targeted radioligand drugs used in the treatment of cancer.
“We believe that Radioligand Therapy has the potential to become a major pillar of cancer treatment. We are also proud to support the communities in which we operate by creating skilled jobs and promoting economic growth,” said Sidonie Golombowski-Daffner, chair and president, Advanced Accelerator Applications.
AAA said the facility will significantly expand the company’s manufacturing capacity in the U.S. and will feature state-of-the-art, advanced manufacturing technologies. The company says the treatment targets specific tumor cells and has less of an impact on surrounding healthy tissue.
The company expects operations to begin in 2023.